15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 24 firms covering Vertex Pharmaceuticals Inc, 20 rate it Buy or better, 3 sit at Hold, and 1 rate it Sell or worse, a strong buy consensus. Targets span $350.00 to $665.00, a moderate spread. The average target of $560.21 sits 6% above the current $528.91. Sentiment has cooled somewhat, with Sell ratings rising from 0 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $4.88 next quarter toward $21.77 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS24 ratings
Strong Buy
Strong Buy00%
Buy2083%
Hold313%
Sell14%
Strong Sell00%
Based on 24 analysts giving stock ratings to Vertex Pharmaceuticals Inc.
As of Sep, 20 of 24 firms rate VRTX a Buy (3 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
VRTX EPS & revenue forecast
EPS · NEXT QUARTER
$4.88
Range $4.27 – $5.40 · 12 analysts · -3% YoY
Next period, 12 analysts expect Vertex Pharmaceuticals Inc to earn $4.88 a share (range $4.27 – $5.40), versus $5.03 a year earlier. Full-year consensus is $16.66, growing to $21.77 the year after.
REVENUE · NEXT QUARTER
$3.5B
Range $3.4B – $3.6B · 12 analysts · +10% YoY
Revenue is expected to reach $3.5B (range $3.4B – $3.6B), +9.5% year-over-year. Full-year consensus is $13.2B, rising to $14.6B next year.
Top analysts covering Vertex Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VRTX.
#1
Andrew Fein
HC Wainwright & Co. · Rank #55
Buy
$641.00+21.2% to target
Overall win rate
46%
+ Follow
#2
Debjit Chattopadhyay
Guggenheim · Rank #113
Buy
$546.00+3.2% to target
Overall win rate
44%
+ Follow
#3
Greg Harrison
Scotiabank · Rank #179
Hold
$558.00+5.5% to target
Overall win rate
38%
+ Follow
#4
Joseph Stringer
Needham · Rank #195
Hold
No targeton VRTX
Overall win rate
36%
+ Follow
#5
TA
Tazeen Ahmad
B of A Securities · Rank #317
Buy
$672.00+27.1% to target
Overall win rate
47%
+ Follow
VRTX stock forecast FAQ
What is VRTX's average 12-month price target?+
The 19 analysts with a live target average $560.21 for Vertex Pharmaceuticals Inc over the next 12 months, ranging from a $665.00 high to a $350.00 low.
Is VRTX stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 24 analyst ratings, 20 are Buy or Strong Buy, 3 are Hold, and 1 are Sell or Strong Sell.
What are the highest and lowest price targets for VRTX?+
The Street-high target is $665.00 (Morgan Stanley), and the Street-low is $350.00 (Baird). The average of all 19 active targets is $560.21.
How many Wall Street analysts cover VRTX?+
24 analysts have an active rating on Vertex Pharmaceuticals Inc, and 19 firms carry a live 12-month price target.
Who is the most accurate analyst covering VRTX?+
Among analysts who currently cover VRTX, Andrew Fein of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #55). Their current call is Buy with a $641.00 target.
What is Vertex Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $4.88 per share (range $4.27 – $5.40) across 12 analysts. Full-year EPS is projected at $16.66, rising to $21.77 the following year.
How much revenue is Vertex Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $3.5B (range $3.4B – $3.6B). Full-year revenue is projected at $13.2B, growing to $14.6B next year.
Have analysts been upgrading or downgrading VRTX lately?+
As of Sep, 20 of 24 firms rate VRTX a Buy (3 Hold, 1 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VRTX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
